ProAssurance Q3 Earnings Miss Estimates on Weak Specialty P&C Unit

PRA misses Q3 EPS estimates as weak Specialty P&C results and higher costs outweigh gains in investment income.

Zacks Investment Research • Nov 7, 2025

ProAssurance Reports Results for Third Quarter 2025

BIRMINGHAM, Ala.--(BUSINESS WIRE)--ProAssurance Corporation (NYSE: PRA), an industry-leading specialty insurer with extensive expertise in medical professional liability, today reported net income of $1.4 million, or $0.03 per diluted share, and operating income(1) of $7.9 million, or $0.15 per diluted share, for the three months ended September 30, 2025. For the nine months ended September 30, 2025, net income was $17.5 million, or $0.34 per diluted share, and operating income was $41.5 millio.

Business Wire • Nov 4, 2025

ProAssurance (PRA) Q3 Earnings and Revenues Miss Estimates

ProAssurance (PRA) came out with quarterly earnings of $0.15 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.34 per share a year ago.

Zacks Investment Research • Nov 5, 2025

ProAssurance (PRA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for ProAssurance (PRA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Nov 5, 2025

3 P&C Insurance Stocks That Have Rallied More Than 25% YTD

Despite higher catastrophe losses, HRTG, PRA, and HCI not only outperform the industry but also crush the Zacks S&P 500 composite and Finance sector.

Zacks Investment Research • Sep 24, 2025

ProAssurance Q2 Earnings Beat Estimates on Declining Expenses

PRA's Q2 earnings top estimates as lower expenses and higher investment income offset weaker premiums.

Zacks Investment Research • Aug 11, 2025

ProAssurance Reports Results for Second Quarter 2025

BIRMINGHAM, Ala.--(BUSINESS WIRE)--ProAssurance Corporation (NYSE: PRA), an industry-leading specialty insurer with extensive expertise in medical professional liability, today reported net income of $21.9 million, or $0.42 per diluted share, and operating income(1) of $26.8 million, or $0.52 per diluted share, for the three months ended June 30, 2025. For the six months ended June 30, 2025, net income was $16.1 million, or $0.31 per diluted share, and operating income was $33.6 million, or $0.

Business Wire • Aug 5, 2025

ProAssurance (PRA) Surpasses Q2 Earnings and Revenue Estimates

ProAssurance (PRA) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.23 per share a year ago.

Zacks Investment Research • Aug 6, 2025

ProAssurance (PRA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for ProAssurance (PRA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Aug 6, 2025

The Doctors Company and ProAssurance Announce Early Termination of the Hart-Scott-Rodino Waiting Period

NAPA, Calif. & BIRMINGHAM, Ala.--(BUSINESS WIRE)--The Doctors Company, the nation's largest physician-owned medical malpractice insurer, and ProAssurance Corporation (NYSE: PRA), an industry-leading specialty insurer with extensive expertise in medical liability, products liability for medical technology and life sciences, and workers' compensation insurance, announced today that on July 2, 2025, the U.S. Federal Trade Commission granted early termination of the waiting period under the Hart-Sc.

Business Wire • Jul 7, 2025